Disease · MONDO_0008977
chondrosarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. chondrosarcoma. Diseases, record MONDO_0008977. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008977
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- chondrosarcoma (disease), chondrosarcoma, malignant, chondrosarcoma, somatic mutation
- Open Targets
- Highest stage of its drugs
- Phase 2, for 24 of its 41 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs41
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| OZEKIBART | CHEMBL5314613 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| REGORAFENIB | CHEMBL1946170 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PATIDEGIB | CHEMBL538867 | Small molecule | Phase 2 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets |
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BELINOSTAT | CHEMBL408513 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CATEQUENTINIB | CHEMBL4303201 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CEDAZURIDINE | CHEMBL3237547 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 41
See all 41 drugsTargets133
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 4 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| TYMS | Thymidylate synthase | 3 | Thymidylate synthase inhibitor | Phase 2 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 2 | Dihydrofolate reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 2 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 2 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Phase 2 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor 1 | 2 | Fibroblast growth factor receptor 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/2260 | Drugs and targets |
1 to 10 of 133
See all 133 targetsTrials28
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03684811 | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Phase 1/2 | 93 | 2023-01-25 | Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations | AZACITIDINE, CISPLATIN, GEMCITABINE, NIVOLUMAB, OLUTASIDENIB | Its record names the disease | ClinicalTrials.gov |
| NCT00073983 | Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma | Phase 2 | 54 | 2012-03-12 | Sarcoma | DOCETAXEL, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT01330966 | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma | Phase 2 | 47 | 2020-02-12 | Chondrosarcoma, Metastatic Chondrosarcoma | PAZOPANIB | Its record names the disease | ClinicalTrials.gov |
| NCT01267955 | Vismodegib in Treating Patients With Advanced Chondrosarcomas | Phase 2 | 45 | 2019-11-15 | Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma, Mesenchymal Chondrosarcoma, Metastatic Chondrosarcoma, Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma | VISMODEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT04458922 | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | Phase 2 | 27 | 2023-10-23 | Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma | ATEZOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04340843 | Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | Phase 2 | 19 | 2025-09-16 | Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma | BELINOSTAT, CEDAZURIDINE, DECITABINE, GUADECITABINE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Phase 1 | 411 | Ewing Sarcoma, Colorectal Adenocarcinoma | CARBOPLATIN, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OZEKIBART, PEMETREXED, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04950075 | Study of INBRX-109 in Conventional Chondrosarcoma | Phase 2 | 206 | Conventional Chondrosarcoma | OZEKIBART | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04521686 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Phase 1 | 200 | Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor | CRELOSIDENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT04055220 | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | Not applicable | 168 | Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Angiosarcoma | REGORAFENIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 28
See all 28 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Treatment (Belinostat, SGI-110) vs Treatment (Belinostat, ASTX727): deaths from any cause | 3 of 6 | 6 of 13 | 19 | NCT04340843 | Trial comparisons |
| Treatment (Belinostat, SGI-110) vs Treatment (Belinostat, ASTX727): serious adverse events | 0 of 6 | 6 of 13 | 19 | NCT04340843 | Trial comparisons |
Papers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 32547189 | RESULT | 1 | PubMed |
| 28039265 | RESULT | 1 | PubMed |
| 41611702 | DERIVED | 1 | PubMed |
| 40882625 | DERIVED | 1 | PubMed |
| 38446419 | DERIVED | 1 | PubMed |
| 37265425 | DERIVED | 1 | PubMed |
| 34552007 | DERIVED | 1 | PubMed |
| 33895682 | DERIVED | 1 | PubMed |
| 31488216 | DERIVED | 1 | PubMed |
| 31401903 | DERIVED | 1 | PubMed |
1 to 10 of 14
See all 14 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008977
GET https://conductscience.org/api/diseases/v1/MONDO_0008977/drugs?page=2